Attached files
| file | filename |
|---|---|
| EX-3.01 - ARTICLES OF MERGER - BANGI INC. | exhibit3-01.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.
20549
FORM 8-K
CURRENT
REPORT
Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of
1934
Date of Report (Date of earliest event reported)
March 29, 2011
COMPASS BIOTECHNOLOGIES
INC.
(Exact name of registrant as specified in its
charter)
| Nevada | 000-52057 | 47-0930829 |
| (State or other jurisdiction of | (Commission File Number) | (IRS Employer |
| incorporation) | Identification No.) |
| 9650 – 20 Avenue, Edmonton, Alberta, Canada | T6N 1G1 |
| (Address of principal executive offices) | (Zip Code) |
Registrant’s telephone number, including area code
780-469-2975
Cyplasin Biomedical Ltd.
(Former
name or former address, if changed since last report.)
Check the
appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions:
[ ] Written communications pursuant
to Rule 425 under the Securities Act (17 CFR 230.425)
[
] Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a -12)
[ ]
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act
(17 CFR 240.14d -2(b))
[ ] Pre-commencement
communications pursuant to Rule 13e-4© under the Exchange Act (17 CFR 240.13e
-4©)
2
| Item 5.03 | Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year |
Effective March 29, 2011, we changed our name from “Cyplasin Biomedical Ltd.” to “Compass Biotechnologies Inc.”, by way of a merger with our wholly owned subsidiary Compass Biotechnologies Inc., which was formed solely for the change of name.
| Item 7.01 | Regulation FD Disclosure |
The name change became effective with the Over-the-Counter Bulletin Board at the opening of trading on March 29, 2011 under our new symbol “COBI”. Our new CUSIP number is 20452Q 103.
| Item 9.01 | Financial Statements and Exhibits |
| 3.01 | Articles of Merger |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| COMPASS BIOTECHNOLOGIES INC. | |
| /s/ Garth Likes | |
| Garth Likes | |
| President | |
| Date: April 4, 2011 |